Saturday 17 October 2026
Export ADIL’s income statement to Excel — free account
Adial Pharmaceuticals, Inc.
ADIL Healthcare Biotechnology
In the quarter to June 2026, EPS fell 150.0% and free cash flow fell 263.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.49
0.35
+11.15%
Follow ADIL
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.55 | 0.03 | 18.19 | 14.23 | 3.41 | 2.37 | 2.67 | 4.90 | 4.16 | 4.42 |
Net Debt/EBITDA |
0.21 | 0.02 | 0.58 | 0.82 | 0.40 | 0.32 | 0.37 | 0.41 | 0.45 | 0.75 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.65 | 0.43 | 0.21 | 0.74 | 0.70 | 0.62 | 0.88 | 1.33 | 0.52 | 0.81 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.17) | 0.00 | 0.00 | 0.00 | 250.00 |
Interest Coverage |
(42.79) | (6.89) | (5.99) | (86.61) | (336.25) | (2,967.49) | (171.83) | — | — | — |
| 76.32% | 206.97% | (675.52%) | (148.36%) | (195.80%) | (518.38%) | (375.32%) | (139.22%) | (323.80%) | (170.73%) | |
| (451.83%) | (1,225.27%) | (491.42%) | (138.81%) | (165.41%) | (299.59%) | (192.79%) | (97.87%) | (269.87%) | (136.16%) | |
ROIC |
0.00% | 0.00% | (763.06%) | (1,417.62%) | 0.00% | 0.00% | 0.00% | (342.64%) | (1,630.29%) | 0.00% |
Return on Tangible Assets |
369.89% | 113.39% | (262.29%) | (120.42%) | (300.05%) | (511.50%) | (425.94%) | (201.26%) | (428.09%) | (166.75%) |
Average Days of Receivables |
0.00 | — | — | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.05 | 0.21 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(52.77) | (95.17) | (328.74) | (401.18) | (383.58) | (404.51) | (278.95) | (119.42) | (35.66) | (9.49) |
Cash per Share |
16.92 | 3.50 | 509.08 | 428.93 | 221.16 | 204.11 | 99.80 | 49.60 | 19.32 | 8.80 |
Shareholders Equity per Share |
(19.90) | (191.85) | 584.38 | 451.94 | 200.31 | 118.11 | 81.71 | 71.64 | 20.96 | 7.89 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(19.90) | (191.85) | 584.38 | 451.94 | 200.31 | 118.11 | 81.71 | 71.64 | 20.96 | 7.89 |
Free Cash Flow |
(0.27) | (0.49) | (2.50) | (6.34) | (7.63) | (12.01) | (11.19) | (6.81) | (6.92) | (6.34) |
Working Capital |
(0.11) | (1.00) | 4.43 | 7.13 | 3.63 | 3.74 | 2.99 | 2.55 | 3.08 | 4.78 |
Capital Expenditures |
— | — | — | — | — | (0.06) | — | — | — | 0.15 |
Net Current Asset Value |
(0.11) | (1.00) | 4.43 | 7.13 | 3.63 | 2.49 | 2.32 | 2.55 | 3.08 | 4.78 |
| Other line items | ||||||||||
Quick Ratio |
0.35 | 0.02 | 15.00 | 12.57 | 2.92 | 2.23 | 2.23 | 4.33 | 3.84 | 4.21 |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.95 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
1,770.32% | 50.53% | (30.06%) | (45.54%) | (91.01%) | (125.54%) | (153.69%) | (98.50%) | (88.54%) | (56.85%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(52.77) | (95.17) | (328.74) | (401.18) | (383.58) | (402.34) | (278.95) | (119.42) | (35.66) | (9.71) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.18) | 0.00 | 0.00 | 0.00 | 0.22 |
Average Payables |
0.18 | 0.18 | 0.22 | 0.14 | 0.42 | 0.47 | 0.28 | 0.19 | 0.18 | 0.45 |
Average Assets |
0.09 | 0.09 | 2.37 | 6.19 | 6.59 | 6.48 | 6.60 | 5.23 | 4.89 | 5.86 |
Average Common Equity |
(0.55) | (0.55) | 1.72 | 5.79 | 5.56 | 3.75 | 3.39 | 3.68 | 4.08 | 4.67 |
Capex to Sales |
— | — | — | — | — | 0.00 | — | — | — | 0.00 |
Columns are period end dates